Supernus Pharmaceuticals, Inc. (LON: 0LB2)
London
· Delayed Price · Currency is GBP · Price in USD
38.69
-0.47 (-1.19%)
Jan 31, 2025, 6:33 PM BST
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $175.69M USD in the quarter ending September 30, 2024, with 14.17% growth. This brings the company's revenue in the last twelve months to $651.97M, up 6.79% year-over-year. In the year 2023, Supernus Pharmaceuticals had annual revenue of $607.52M, down -8.95%.
Revenue (ttm)
$651.97M
Revenue Growth
+6.79%
P/S Ratio
n/a
Revenue / Employee
$999.96K
Employees
652
Market Cap
1.70B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
Dec 31, 2019 | 392.76M | -16.14M | -3.95% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Supernus Pharmaceuticals News
- 6 weeks ago - Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada - GlobeNewsWire
- 2 months ago - Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth - Seeking Alpha
- 3 months ago - Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - GlobeNewsWire
- 3 months ago - Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - GlobeNewsWire